{"id":5960,"date":"2020-09-09T10:03:56","date_gmt":"2020-09-09T08:03:56","guid":{"rendered":"http:\/\/www.seventure.fr\/?p=5960"},"modified":"2020-09-09T10:03:56","modified_gmt":"2020-09-09T08:03:56","slug":"lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/","title":{"rendered":"LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,105],"tags":[],"class_list":["post-5960","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-microbiome-nutrition-foodtech-lifestyle"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ra\u00efssa Brian\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/\",\"url\":\"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/\",\"name\":\"LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2020-09-09T08:03:56+00:00\",\"author\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/6bb6ba61919ee7bed3cdfed85c80b7cc\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/6bb6ba61919ee7bed3cdfed85c80b7cc\",\"name\":\"Ra\u00efssa Brian\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a3c9d77aa3b5710ecfb5f296b732614d01c3916db85dc815445444b88a767b61?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a3c9d77aa3b5710ecfb5f296b732614d01c3916db85dc815445444b88a767b61?s=96&d=mm&r=g\",\"caption\":\"Ra\u00efssa Brian\"},\"url\":\"https:\/\/www.seventure.fr\/en\/author\/raissa\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/","twitter_misc":{"Written by":"Ra\u00efssa Brian"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/","url":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/","name":"LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2020-09-09T08:03:56+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/6bb6ba61919ee7bed3cdfed85c80b7cc"},"breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-on-xla1-for-the-treatment-of-obesity-and-metabolic-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/6bb6ba61919ee7bed3cdfed85c80b7cc","name":"Ra\u00efssa Brian","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a3c9d77aa3b5710ecfb5f296b732614d01c3916db85dc815445444b88a767b61?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a3c9d77aa3b5710ecfb5f296b732614d01c3916db85dc815445444b88a767b61?s=96&d=mm&r=g","caption":"Ra\u00efssa Brian"},"url":"https:\/\/www.seventure.fr\/en\/author\/raissa\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/5960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=5960"}],"version-history":[{"count":1,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/5960\/revisions"}],"predecessor-version":[{"id":5961,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/5960\/revisions\/5961"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=5960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=5960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=5960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}